Bausch + Lomb Reports Q1 2026 Earnings with Revenue Growth and Strong Performance Across Segments
Bausch + Lomb (BLCO) reported Q1 2026 earnings with total revenue of $1.244 billion, a 6% increase in constant currency. The company saw strong performance across its Vision Care, Pharmaceuticals, and Surgical segments, with notable growth in products like LUMIFY and Xiidra. Adjusted EBITDA rose 59% year-over-year to $200 million.
Tickers: $BLCO
Topics: Earnings Financial Performance Margin Improvement Revenue Growth Segment Revenue